Saturna Capital Corp Has $63.66 Million Stock Position in Agilent Technologies, Inc. $A

Saturna Capital Corp cut its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 26.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 539,400 shares of the medical research company’s stock after selling 196,344 shares during the period. Saturna Capital Corp’s holdings in Agilent Technologies were worth $63,655,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of A. Resona Asset Management Co. Ltd. raised its holdings in Agilent Technologies by 6.2% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock valued at $11,631,000 after buying an additional 5,767 shares during the last quarter. TrueMark Investments LLC bought a new stake in Agilent Technologies during the 2nd quarter worth approximately $1,999,000. Fenimore Asset Management Inc increased its position in Agilent Technologies by 2.7% in the 2nd quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock valued at $21,346,000 after acquiring an additional 4,823 shares during the period. Nuance Investments LLC lifted its holdings in shares of Agilent Technologies by 13.5% during the second quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock worth $9,523,000 after purchasing an additional 9,628 shares during the period. Finally, Carmel Capital Partners LLC grew its stake in shares of Agilent Technologies by 32.3% in the second quarter. Carmel Capital Partners LLC now owns 10,928 shares of the medical research company’s stock worth $1,290,000 after purchasing an additional 2,667 shares during the last quarter. 87.41% of the stock is currently owned by institutional investors.

Agilent Technologies Price Performance

Shares of NYSE A opened at $143.86 on Wednesday. The firm has a market capitalization of $40.78 billion, a P/E ratio of 33.77, a P/E/G ratio of 4.67 and a beta of 1.29. The firm’s 50-day moving average price is $138.31 and its 200-day moving average price is $124.52. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $153.84.

Agilent Technologies (NYSE:A) last issued its earnings results on Wednesday, August 27th. The medical research company reported $1.37 EPS for the quarter, meeting analysts’ consensus estimates of $1.37. Agilent Technologies had a return on equity of 25.51% and a net margin of 17.97%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the previous year, the company posted $1.32 EPS. The firm’s revenue was up 10.1% compared to the same quarter last year. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. Equities research analysts anticipate that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, October 22nd. Investors of record on Tuesday, September 30th were issued a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Tuesday, September 30th. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.24%.

Insider Transactions at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 12,490 shares of Agilent Technologies stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $150.00, for a total value of $1,873,500.00. Following the completion of the sale, the chief executive officer owned 33,448 shares of the company’s stock, valued at approximately $5,017,200. This trade represents a 27.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.26% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on A. Robert W. Baird lifted their price objective on Agilent Technologies from $141.00 to $142.00 and gave the stock an “outperform” rating in a research note on Thursday, August 28th. Wall Street Zen raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Friday, October 3rd. JPMorgan Chase & Co. boosted their target price on shares of Agilent Technologies from $155.00 to $165.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Rothschild Redb raised Agilent Technologies to a “strong-buy” rating in a research report on Wednesday, October 8th. Finally, UBS Group upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $130.00 to $170.00 in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.62.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.